ARTBIO

Executive Summary

ARTBIO is a private radiopharmaceutical company headquartered in Oslo, Norway, founded in 2021. The company is pioneering a new class of alpha radioligand therapies designed to deliver targeted radiation to cancer cells while minimizing damage to healthy tissue. By leveraging alpha-emitting isotopes, ARTBIO aims to overcome limitations of beta-based therapies, potentially offering higher potency and improved efficacy against a broad range of solid tumors. The company is currently in Phase 2 clinical development, focusing on advancing its lead candidate through proof-of-concept trials. ARTBIO is also building an integrated ecosystem to maximize the potential of its platform, including proprietary isotope production and delivery technologies. Although still private and not yet generating revenue, ARTBIO's innovative approach positions it as a notable player in the rapidly evolving radiopharmaceuticals space, where the convergence of precision medicine and targeted radiotherapy is attracting significant investment and partnership interest.

Upcoming Catalysts (preview)

• Q1 2027Phase 2 clinical data readout for lead candidate60% success
• Q4 2026Strategic partnership with a large pharma for co-development or licensing50% success
• Q3 2026Series B or later-stage financing round to fund pipeline expansion70% success